We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Standard Phantom Developed for Breast Cancer MRIs

By HospiMedica International staff writers
Posted on 03 Apr 2016
The US National Institute of Standards and Technology (NIST; Gaithersburg, MD, USA) has developed a standardized phantom to help test the performance of magnetic resonance imaging (MRI) devices used to identify and monitor breast cancer.

The NIST phantom will help standardize and ensure quality control of breast tissue MRIs when comparing images within and between medical research studies, comparing MRI scanner performance, and the training of operators. More...
The phantom is composed of a flexible, soft 15 cm × 12.5 cm silicone shell, with internal components made of rigid polycarbonate to ensure regular geometry. The phantom also supports quantitative MRI, which is increasingly being used for breast cancer diagnosis, staging, and treatment monitoring.

The phantom has two basic types of internal arrangements, which can be paired for MRI scans. One unit, designed for conventional MRI scans, is based on the magnetic properties of hydrogen atoms. It contains four layers of small plastic spheres filled with solutions that mimic tissue, including corn syrup in water to represent fibroglandular tissue, and grapeseed oil to represent fat; the spheres can be customized to meet special clinical needs. Potential options include solutions that would mimic either benign cysts or calcium microcalcifications, which can signal cancer.

The second phantom unit is designed for the newer technique of diffusion MRI, which measures the motion of water molecules within breast tissue. The second unit contains plastic vials filled with varying concentrations of a polyvinylpyrrolidone (PVP), a nontoxic polymer which is tuned to mimic the differing diffusion properties of malignant and benign tumors. Both units have a modular design to help fit them into different MRI systems. The development process of the new phantom was published on March 6, 2016, in JMRI.

“The biggest design challenge was to create a lifelike mimic of both fat and fibroglandular tissue. The design success led to industry’s rapid commercialization of the phantom, currently used by five research groups,” said lead author and NIST project leader Katy Keenan, PhD. “I believe the NIST phantom can have a big impact, especially because we are seeing more use of quantitative MRI for breast cancer. It will be used by both researchers developing new techniques and by radiologists using techniques in the clinic.”

Related Links:

US National Institute of Standards and Technology



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Multi-Chamber Washer-Disinfector
WD 390
Resorbable Bovine Collagen Membrane
GenDerm
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Graphical Abstract (Aoibhin M. Sheedy et al., A replenishable peritoneal implant for localized delivery and peritoneal fluid sampling in ovarian cancer, Device (2026). DOI: 10.1016/j.device.2026.101050)

New Implant Provides Sustained Localized Therapy for Ovarian Cancer

Ovarian cancer is often diagnosed at advanced stages because symptoms such as bloating, pain, and pelvic pressure are nonspecific. Standard care relies on surgery and systemic therapy, yet tools for targeted... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.